Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Has this study been replicated?
The atlas records 1 replication of this study. Recorded outcomes: 1 mixed. The earliest on record is from 2017.
Replications
- Replication Study: Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia, Shan et al. (2017). eLife. Outcome recorded: mixed.
We found treatment of MLL-fusion leukaemia cells (MV4;11 cell line) with the BET bromodomain inhibitor I-BET151 resulted in selective growth inhibition
Outcome read from the abstract. View paper
Cite this record
Dawson, M. A., Prinjha, R. K., Dittmann, A., Giotopoulos, G., Bantscheff, M., Chan, W.-I., Robson, S. C., Chung, C., Hopf, C., Savitski, M. M., Huthmacher, C., Gudgin, E., Lugo, D., Beinke, S., Chapman, T. D., Roberts, E. J., Soden, P. E., Auger, K. R., Mirguet, O., … Kouzarides, T. (2011). Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature, 478(7370), 529–533. https://doi.org/10.1038/nature10509
Other studies in the atlas
Failed replications · Successful replications · All browse pages